Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
McKinsey
Mallinckrodt
Baxter
Express Scripts

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

ENDO PHARM Company Profile


Email this page to a colleague

« Back to Dashboard

Drugs and US Patents for ENDO PHARM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-005 Feb 29, 2008 DISCN Yes No 8,309,112 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Endo Pharms Inc NASCOBAL cyanocobalamin SPRAY, METERED;NASAL 021642-001 Jan 31, 2005 RX Yes Yes 8,940,714 ⤷  Free Forever Trial ⤷  Free Forever Trial
Endo Pharms MOBAN molindone hydrochloride CAPSULE;ORAL 017111-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
Endo Pharms FROVA frovatriptan succinate TABLET;ORAL 021006-001 Nov 8, 2001 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial
Endo Pharms Inc NASCOBAL cyanocobalamin SPRAY, METERED;NASAL 021642-001 Jan 31, 2005 RX Yes Yes 7,404,489 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-001 Jun 22, 2006 DISCN Yes No 8,309,112 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ENDO PHARM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharms MOBAN molindone hydrochloride TABLET;ORAL 017111-008 Approved Prior to Jan 1, 1982 3,491,093 ⤷  Free Forever Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-002 Jun 22, 2006 5,128,143 ⤷  Free Forever Trial
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 6,592,903 ⤷  Free Forever Trial
Endo Pharms FROVA frovatriptan succinate TABLET;ORAL 021006-001 Nov 8, 2001 5,917,054 ⤷  Free Forever Trial
Endo Pharms FROVA frovatriptan succinate TABLET;ORAL 021006-001 Nov 8, 2001 5,464,864 ⤷  Free Forever Trial
Endo Pharm SUPPRELIN LA histrelin acetate IMPLANT;SUBCUTANEOUS 022058-001 May 3, 2007 5,266,325 ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ENDO PHARM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Gel 10 mg/actuation ➤ Subscribe 2012-08-14
➤ Subscribe Extended-release Tablets 7.5 mg and 15 mg ➤ Subscribe 2008-05-29
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2011-03-09
➤ Subscribe Nasal Spray 500 mcg/spray ➤ Subscribe 2017-04-28
➤ Subscribe Extended-release Tablets 5 mg, 10 mg, 20 mg and 40 mg ➤ Subscribe 2007-11-23
➤ Subscribe Extended-release Tablets 30 mg ➤ Subscribe 2008-06-12
➤ Subscribe Injection 250 mg/mL ➤ Subscribe 2014-06-11

Supplementary Protection Certificates for ENDO PHARM Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0694547 2002/028 Ireland ⤷  Free Forever Trial PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
0694547 03C0003 France ⤷  Free Forever Trial PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
0591280 01C0019 France ⤷  Free Forever Trial PRODUCT NAME: FROVATRIPTAN SUCCINATE MONOHYDRATE; NAT. REGISTRATION NO/DATE: NL 24548 20001212; FIRST REGISTRATION: FR - NL 24548 20001212
0591280 SPC/GB03/014 United Kingdom ⤷  Free Forever Trial PRODUCT NAME: 3 METHYLAMINO-6-CARBOXAMIDO-1, 2, 3, 4-TETRAHYDROCARBAZOLE ("FROVATRIPTAN") INCLUDING A SALT, SOLVATE OR HYDRATE THEREOF; REGISTERED: FR NL 24548 20001212; UK PL 16239/0017 20021007; UK PL 16239/0018 20021007
0591280 C300103 Netherlands ⤷  Free Forever Trial PRODUCT NAME: FROVATRIPTAN EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 27211RVG 27212 2002190419; FIRST REGISTRATION: NL 24548 20001212
0694547 C300071 Netherlands ⤷  Free Forever Trial PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Johnson and Johnson
Colorcon
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.